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ments) and University of Arizona (UA) patients who were
treated in the hospital (n  27, 72 treatments). All
healthcare resources and treatment outcomes were ob-
tained for each episode of FN. Uniform charge values
were applied to each healthcare resource. Outcome data
included positive blood cultures and days to resolution of
FN, based upon fever and absolute neutrophil count. We
applied Mann-Whitney U and chi square tests. Sensitivity
analyses were performed using charges per episode. 
RESULTS: Both groups were similar for gender, age, types
of diseases, and FN-inducing chemotherapies. More of the
home-treated patients were treated with granulocyte colony
stimulating factor (58 versus 42, p  0.004). The median
total estimated charge per episode was $9166 for UA pa-
tients versus $5117 for UNM patients (p  0.001). Lower
charges for UNM patients, included hospital days, microbi-
ology cultures, blood counts, serum chemistries, physician
visits, radiologic studies, and serum antibiotic levels. Posi-
tive blood cultures occurred more frequently in UA patients
(30.6% versus 11.1%, p  0.012) and mean days to reso-
lution of FN was 8.6 versus 7.6 for UNM patients (NS).
Results were stable across all sensitivity analyses. 
CONCLUSION: With careful supervision by a pediatric
oncology center, uncomplicated FN can be treated by
home care, with substantial savings.
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THE VALUE OF HOME CARE IN METASTATIC 
BREAST CANCER MANAGEMENT: MODELING 
ORAL VERSUS INTRAVENOUS CHEMOTHERAPY 
AT HOME AND AT AN OUTPATIENT CLINIC
Mathes A, Hay J
University of Southern California, Los Angeles, CA, USA
Few studies have investigated the cost-effectiveness of
oral chemotherapeutic agents that are used to treat meta-
static breast cancer (MBC) at home and in clinic settings. 
OBJECTIVE: This study assessed the value of MBC man-
agement using intravenous (IV) and oral chemotherapeu-
tic agents. 
METHODS: A predictive data collection approach
(modeling) was used to perform this cost-effectiveness
analysis. Data were used from existing economic com-
parisons between home care and clinic care, from clinical
trials, and using Medicare cost data in 1998 US dollars.
A societal perspective was used to compare the cost-effec-
tiveness of the following first-line chemotherapy regi-
mens: C*MF (oral cyclophosphamide [C*], IV metho-
trexate [M], IV fluoruracil [F]), and AC (IV doxorubicin
[A] and IV cyclophosphamide) at home and at an outpa-
tient clinic; and the second-line regimens: IV paclitaxel
(P), oral etoposide (E*), oral idarubicin (I*), and oral
UFT (U*) at home and at an outpatient clinic. 
RESULTS: C*MF, administered at home, was the most
cost-effective first-line strategy (34,163 $/QALY). The
home AC regimen was more costly, and more effective. It
was not, however, cost-effective relative to the home
C*MF strategy because the incremental cost-effectiveness
(ICE) between the two strategies was 1,763,990 $/QALY.
E*, administered at home, was found to be the most cost-
effective second-line strategy (33,789 $/QALY). Other
strategies (home P, clinic I*, and home I*) were more
costly, but more effective. These strategies, however, were
not cost-effective relative to home E* because the ICE be-
tween these strategies and E* were 945,101 $/QALY,
369,232 $/QALY, and 175,523 $/QALY, respectively. 
CONCLUSIONS: These results suggest that oral chemo-
therapeutic agents, administered at home, provide a cost-
effective means of treating MBC.
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RELIABILITY AND VALIDITY OF THE BREAST 
EVALUATION QUESTIONNAIRE (BEQ): 
AN OUTCOME MEASURE FOR BREAST
IMPLANT STUDIES
Lenderking WR, Tafesse E
Abt Associates Clinical Trials, Cambridge, MA, USA
OBJECTIVE: This study was undertaken to determine the
optimal scoring for the Breast Evaluation Questionnaire
(BEQ), and to provide evidence for its validity as a mea-
sure of comfort and satisfaction for women undergoing
breast augmentation for cosmetic reasons. The BEQ is a
55-item questionnaire. A 76-item version was previously
validated in a sample of undergraduate women (non-clini-
cal sample). The BEQ measures satisfaction with breast at-
tributes, and comfort with general appearance and appear-
ance of breasts while fully dressed, in a bathing suit, and
while naked, across a variety of situations. 
METHODS: We conducted exploratory factor analysis in
1244 women at baseline prior to the augmentation proce-
dure. We conducted analysis of reliability of the factors, ex-
amined discriminant validity of the items of the BEQ, and
examined associations between the BEQ factors and widely
used measures of self-esteem and body-self relations. 
RESULTS: The factor analysis indicated that the BEQ is op-
timally scored as three factors: Comfort Not Fully Dressed,
Comfort Fully Dressed, and Satisfaction with Breast At-
tributes. These factors form internally consistent subscales,
which remain reliable over time (Cronbach’s  minimum
value across four visits was .89 for all three factors). We
demonstrated that the items have discriminant validity. The
factors are moderately correlated with the Appearance Eval-
uation subscale of the Multi-Dimensional Body Self Rela-
tions Questionnaire (MBSRQ) and the Physical Self sub-
scale of the Tennessee Self-Concept Scale (TSC). 
CONCLUSIONS: The BEQ can now be scored with
greater simplicity and greater ease of interpretation than
was previously indicated.
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OBJECTIVE: The objective of this study was to compare
the McMaster’s Health Utilities Index-Mark III and the
EuroQol-5D in a surgical breast cancer population. 
METHODS: Seventy-five surgical breast cancer patients
participated in the study. The patients were given the
Mark III version of the Health Utilities Index (HUI), and
the EuroQol-5D (EQ) comprising both the classification
system and the thermometer at the same visit, and the or-
der of instrument administration was randomized. Infor-
mation on the age of the patient, the cancer stage, and
the number of comorbidities was obtained through chart
review. 
RESULTS: The mean age of patients was 60 (sd  10.7).
Ninety-six percent of the patients were diagnosed with ei-
ther stage I or II breast cancer. The majority of patients
had up to three comorbid conditions. The mean score on
the HUI was 84.6 (sd  16.8). The mean on the EQ clas-
sification system was 87.4 (sd  13.6), while that on the
EQ thermometer was 86.6 (sd  12.6). The correlation
coefficient between scores on the HUI and the EQ classi-
fication system was 0.54, while that between the HUI
and the EQ thermometer score was 0.66. Eight patients
(10.6%) recorded the highest score on the HUI, 36 patients
(48%) on the EQ classification system, while 12 patients
(16%) indicated “best imaginable health state” on the EQ
thermometer. The EQ classification system classified the
patients into 15 health states, while 33 health states on the
HUI classification system described the sample. 
CONCLUSION: The results of this study show that al-
though both the HUI and the EQ classification systems
are reliable measures of health status, they differ in terms
of instrument sensitivity to disease severity.
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INITIAL, MAINTENANCE, AND TERMINAL CARE 
COSTS OF BREAST CANCER TREATMENT
Noe LL1, Vreeland MG1, Gore MG2, Trotter JP1
1Ovation Research Group, Highland Park, IL, USA; 2Zeneca 
Pharmaceuticals, Wilmington, DE, USA
OBJECTIVE: A retrospective claims analysis was per-
formed examining costs of care for breast cancer patients. 
METHODS: Two years of claims data (1/94 to 12/95)
were obtained from a provider of cancer care services to
managed care organizations. Patients with a breast cancer–
related medical claim (ICD-9 code of 174.X) were staged
according to the following criteria. Stage I: lumpectomy,
with no chemotherapy prior to or following lumpectomy,
and no ICD-9 code of 196.X; stage II: ICD-9 code of
196.3; stage III: ICD-9 code of 196.X, but not 196.3; stage
IV: ICD-9 code of 197, 198, or 199. Costs, reflecting the
amount reimbursed by the insurer, were calculated based
on medical and pharmacy resource utilization. Average pe-
riod costs were reported for each stage according to three
time frames: initial (6 months), maintenance (3 months),
and terminal (6 months). 
RESULTS: A total of 1822 female patients had a breast
cancer–related medical claim during this period; 530 pa-
tients were considered evaluable based upon available data.
Stage I patients had the lowest overall costs ($9572), while
stage IV patients experienced the highest overall costs
($34,448). Too few stage III patients (n  19) were identi-
fied to draw conclusions. Overall, highest costs were ob-
served during the terminal period. When data from all pa-
tients were analyzed, per-patient costs were $7183 over an
initial 6-month period, $3901 over a 3-month maintenance
period, and $12,080 over a 6-month terminal period. 
CONCLUSIONS: These results indicate that breast can-
cer patients in this setting utilized substantial medical re-
sources, particularly during the terminal phase of care,
and that utilization, in general, increased with stage.
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AN ANALYSIS OF RESEARCH AND POLICY-
RELEVANT CHARACTERISTICS OF QUALITY 
OF LIFE ASSESSMENTS IN PROSTATE CANCER
Sommers SD1, Ramsey SD2
1Department of Pharmacy, University of Washington, Seattle, 
WA, USA; 2Department of Medicine, University of 
Washington, Seattle, WA, USA
OBJECTIVE: The purpose of this study was to review
the HRQoL literature and to determine its usefulness for
assessing the impacts of alternative treatments for pa-
tients with prostate cancer. 
METHODS: A structured search was conducted of
widely available databases to identify studies of HRQoL
applied to prostate cancer, using the following inclusion
criteria: English language literature, original research,
peer-reviewed journal publication, inclusion of 10 or
more patients, and presence of a comparison group.
Manuscripts were analyzed for the type of HRQoL eval-
uated (generic versus disease-specific) prostate cancer–
related health domains analyzed, within- and between-
treatment HRQoL impacts, comparators used, and distri-
bution of studies across cancer stages and treatments. 
RESULTS: Over half (56%) of the 41 HRQoL studies as-
sessed the impact of single-treatment options without re-
gard to other available treatments; 44% compared two
or more therapies. Generic, non-disease-specific instru-
ments detected treatment-related changes in HRQoL in
2/15 (13%) instances. In contrast, 92% (11/12) of the
prostate cancer–specific instrument assessments detected
differences in HRQoL. Four of 14 reported prostate can-
cer–specific instruments are standardized and well vali-
Stage n
Initial
costs
Maintenance
costs
Terminal
costs
Total
costs
I 228 $4,169 $1,992 $3,411 $9,572
II 87 $6,371 $3,131 $5,176 $14,678
III 19 $637 $557 $7,905 $9,099
IV 196 $12,159 $5,602 $16,687 $34,448
All 530 $7,183 $3,901 $12,080 $23,164
